Medicare is launching a temporary bridge program that will cover select GLP-1 weight-loss medications from two of the pharmaceutical industry’s largest players.
The program will extend coverage to Novo Nordisk’s (CPH: NOVO-B) Wegovy, both in injection and tablet form, marking a significant shift in how the federal health program approaches obesity treatment.
Eli Lilly’s (NYSE: LLY) Zepbound KwikPen formulation and its Foundayo tablets are also included in the coverage arrangement, broadening patient access to the increasingly popular drug class.
GLP-1 receptor agonists have transformed the obesity and diabetes treatment landscape over the past several years, generating tens of billions of dollars in combined annual revenues for both Novo Nordisk and Lilly.
The Medicare bridge program represents a critical interim measure designed to ensure continuity of access for eligible beneficiaries while longer-term coverage frameworks are finalized.
Demand for GLP-1 medications has consistently outpaced supply projections, and federal coverage decisions carry enormous weight for pharmaceutical manufacturers tracking volume and pricing trends.
Both Novo Nordisk and Eli Lilly have made substantial manufacturing investments to scale production of their respective GLP-1 products in response to surging global demand.
Wegovy, Novo Nordisk’s flagship obesity drug, has been one of the most closely watched pharmaceutical products in recent years given its strong clinical weight-loss outcomes and growing physician adoption.
Lilly’s Zepbound has similarly captured significant market attention, with the company reporting strong uptake across multiple patient populations since the product’s commercial launch.
The inclusion of both injections and oral tablet formulations in the Medicare bridge program signals a broadening recognition that patient preferences for delivery method must be accommodated in coverage policy.
Federal coverage of GLP-1 drugs through Medicare has been a politically and fiscally contested issue, given the high list prices associated with these medications and the scale of the Medicare beneficiary population.
The bridge program’s temporary designation suggests policymakers are moving cautiously, using the arrangement as a transitional mechanism ahead of more permanent reimbursement decisions.
